Searchable abstracts of presentations at key conferences in endocrinology
Previous issue | Volume 38 | SFEBES2015 | Next issue

Society for Endocrinology BES 2015

Edinburgh, UK
02 Nov 2015 - 04 Nov 2015

Card image cap
2-4 November 2015, Edinburgh, UK Further information

Clinical Management Workshops

Workshop 3: Biological therapies - cause and cure of endocrine diseases

ea0038cmw3.1 | Workshop 3: Biological therapies - cause and cure of endocrine diseases | SFEBES2015

The thyroid and rituximab

Salvi Mario

Since our first report on successful treatment of one patient with moderate-severe GO in 2006, several non-controlled studies have suggested that RTX can be more effective in active GO than intravenous methylprednisolone (ivMP). One randomised controlled trial comparing RTX to placebo and one comparing RTX to steroids in moderate-severe GO were recently published.We have randomised 32 patients with active moderate-severe GO to be treated with RTX or ivMP...

ea0038cmw3.2 | Workshop 3: Biological therapies - cause and cure of endocrine diseases | SFEBES2015

Endocrine sequelae of biological therapies (Campath, other MABs, etc.)

Moran Carla

Biological therapies include interleukins, interferons, and MABs. Over the past few years, the use of MAB to treat cancer and other diseases such as multiple sclerosis (MS) have increased; some of these frequently cause endocrine side effects.Alemtuzumab, a MAB directed at CD52 on T and B lymphocytes, is very effective in reducing relapse rates and improving disability in relapsing remitting MS, however is frequently (16–35%) associated with the ons...